Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Liabilities (2019 - 2026)

InMed Pharmaceuticals has reported Total Liabilities over the past 5 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 30.88% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 30.88%, while the annual FY2025 figure was $2.1 million, 18.0% down from the prior year.
  • Total Liabilities for Q4 2025 was $1.6 million at InMed Pharmaceuticals, down from $1.8 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $5.2 million in Q4 2021 and troughed at $1.3 million in Q3 2023.
  • A 5-year average of $2.6 million and a median of $2.3 million in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 69.85% in 2022 and later tumbled 62.55% in 2023.
  • Year by year, Total Liabilities stood at $5.2 million in 2021, then plummeted by 50.45% to $2.6 million in 2022, then fell by 3.92% to $2.5 million in 2023, then fell by 6.57% to $2.3 million in 2024, then plummeted by 30.88% to $1.6 million in 2025.
  • Business Quant data shows Total Liabilities for INM at $1.6 million in Q4 2025, $1.8 million in Q3 2025, and $2.1 million in Q2 2025.